UK markets closed

Sareum Holdings plc (SAR.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
30.50-3.00 (-8.96%)
At close: 05:15PM BST

Sareum Holdings plc

Langford Arch
Unit 2A London Road Pampisford
Cambridge CB22 3FX
United Kingdom
44 1223 497 700
https://www.sareum.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees5

Key executives

NameTitlePayExercisedYear born
Dr. Timothy John Mitchell Ph.D.Founder, CEO & Executive Director207.85kN/A1960
Dr. John Charles Reader Ph.D.Founder, Chief Scientific Officer & Executive Director205.8kN/A1967
Mr. Clive H. W. Birch F.C.A.Senior Independent Non-Executive Director & Secretary25kN/A1954
Alexandra HarrisonHead of IRN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

Sareum Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.